Immunovia AB (IMMVF)
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Sector: Medical - Diagnostics & Research
Industry: Medical - Diagnostics & Research
Immunovia AB
- 0.2%
- 1.5M
- 999.99
Float 654.34M · FMP free float
The cost to borrow IMMVF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 1.5M sh |
| Oct 15, 2026 | 1.4M sh |
| Sep 30, 2026 | 1.7M sh |
| Sep 15, 2026 | 1.8M sh |
| Aug 31, 2026 | 2.1M sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for IMMVF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 1,456,901 IMMVF shares were sold short (0.22% of a 654.34M-share float, 999.99 days to cover).